The first one is a phase 1–2 trial exploring the combination of a standard treatment (chemotherapy +/- biological agents) plus Durvalumab (anti-PD-L1 mAb) and Monalizumab (anti-NKG2A mAb) in patients with selected advanced solid tumors (including CRC) who have not received prior immunotherapy. The gene discussed is KLRC1; the disease is colorectal carcinoma.